Proapoptotic Genes BAX and CD40L as Predictors of Bladder Cancer Survival
Author Information
Author(s): Hussain S A, Ganesan R, Hiller L, Murray P G, El-Magraby M M, Young L, James N D
Primary Institution: Cancer Research UK Institute For Cancer Studies, University of Birmingham
Hypothesis
The expression levels of proapoptotic genes BAX and CD40L can predict survival outcomes in patients with transitional cell carcinoma of the bladder.
Conclusion
Higher expression of the proapoptotic gene BAX and the CD40L is associated with improved survival in bladder cancer patients.
Supporting Evidence
- Patients with high BAX expression had a median survival of 110 months compared to 18 months for those with low expression.
- Overexpression of CD40L was significantly associated with improved survival outcomes.
- Statistical analysis showed significant associations between BAX, CD40, and CD40L expression levels.
Takeaway
This study found that certain genes can help doctors predict how long bladder cancer patients might live, with some genes linked to better survival.
Methodology
Immunohistochemical analysis of paraffin-embedded tissue samples from 94 patients with transitional cell carcinoma of the bladder.
Potential Biases
Potential biases may arise from the selection of patients and the subjective nature of immunohistochemical staining evaluations.
Limitations
The study's findings may not be generalizable due to the specific patient population and the retrospective nature of the analysis.
Participant Demographics
The study included 94 patients (74 males, 20 females) with a median age of 67 years.
Statistical Information
P-Value
0.0002
Confidence Interval
95% CI 1.34–2.33
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website